Owen Mumford Appoints Shirley Loh Regional Managing Director for Asia-Pacific

Food and Healthcare Press Releases Monday October 1, 2018 08:33
OXFORD, England--1 Oct--PRNewswire/InfoQuest

Owen Mumford, global industry leader in medical device design and manufacturing, has announced the appointment of Shirley Loh as Regional Managing Director for Asia-Pacific based at the company's Malaysian hub in Nusajaya.

(Photo: https://mma.prnewswire.com/media/750921/Owen_Mumford.jpg )

Loh, who takes up the position from today, has both clinical and commercial experience. For the past six years she has worked for Medtronic where most recently she was Marketing Director for Medtronic's Restorative Therapy Group in ASEAN (Association of Southeast Asian Nations).

Commenting on the appointment, Owen Mumford's Group Managing Director Jarl Severn says, "We are delighted that Shirley is joining the business. Our Malaysian hub was Owen Mumford's first manufacturing facility to open outside the UK and in the past three years we have seen strong growth across the Asia-Pacific region. However, given the growing prevalence of conditions such as diabetes, particularly in the emerging markets, I believe Owen Mumford has a greater role to play in the management of the condition across the region. Shirley has worked in the medical device sector for more than two decades and has both the skills and the experience to further establish our brand in this market."

Loh welcomes the opportunity to lead the Malaysian team and from Day One she will focus on establishing an effective and efficient market access strategy.

Speaking about her priorities she comments, "I am very excited to be joining Owen Mumford as they focus on expansion in the Asia-Pacific region. The market here is very established but we recognise that there is considerable growth in demand."

"A report from the World Health Organisation in 2014 set the global figure of those with diabetes at 422m, with a higher prevalence in the emerging markets within the region. This includes China where more than 11% of adults are believed to have the condition[1]."

Loh continues, "These figures are clearly very worrying and as a responsible business Owen Mumford has a key role to play in identifying how we can support the developing markets most effectively, helping to raise awareness and improve communications, as well as using innovation to deliver a service to these markets."

"I look forward to establishing Owen Mumford's role in tackling this issue and also to generating more awareness of our capabilities as a business, both as a medical device supplier and as a partner in delivering innovative healthcare solutions."

Loh lives with her husband and two teenage daughters in Singapore, and outside of work, she enjoys spending time with the family.
About Owen Mumford

Headquartered in Oxford, England, medical device manufacturer Owen Mumford also has offices in USA, France, Germany, Mexico and Malaysia, and specialist distributors across five continents. The company, which develops pioneering medical devices, has been operating a regional hub in Nusajaya, in the south of Malaysia since 2016. The site includes packaging, manufacturing and logistics services for its customer base throughout the region.

[1] https://jamanetwork.com/journals/jama/fullarticle/1734701
Contact details:
Gillian Gibbons
Source: Owen Mumford

Latest Press Release

BioNet reports on persistence of antibody responses of recombinant pertussis vaccines in the Lancet Infectious Diseases

Publications report the sustained higher antibody responses of BioNet acellular pertussis vaccines containing genetically inactivated pertussis toxin (PTgen) and the new opportunities to control the resurgence of whooping cough disease BioNet announced...

The Menarini Group Announces Meropenem/vaborbactam European Marketing Authorization

- Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections - The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in...

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive...

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

Related Topics